Unicycive Therapeutics (UNCY) Inventory Average (2026)
Unicycive Therapeutics' (UNCY) quarterly Inventory Average came in at $7.6 million in Q2 2026, up 10.17% quarter-over-quarter from $6.9 million in Q1 2026.
Powered by 
Analysis
Unicycive Therapeutics (UNCY) Inventory Average (2026) Analysis & Trends
Unicycive Therapeutics (UNCY) has reported Inventory Average for 1 consecutive years, with $7.6 million the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Inventory Average changed N/A year-over-year to $7.6 million; the trailing twelve-month figure through Jun 2026 stood at $7.6 million (changed N/A YoY), and the FY2025 full-year result was $4.9 million, changed N/A from the prior year.
- Inventory Average improved to $7.6 million in Q2 2026 per UNCY's latest filing, from $6.9 million in the prior quarter.
- Across five years, Inventory Average topped out at $7.6 million in Q2 2026 and bottomed at $6.9 million in Q1 2026.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inventory Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 6.20 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | 1.93 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 1.77 Bn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 3.09 Bn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | 213.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 90.57 Mn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 2.17 Bn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | - |
| 10 | Unicycive Therapeutics | 143.47 Mn | 143.47 Mn | - | 7.65 Mn |